BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, April 16, 2026
Home » Authors » Omar Ford

Articles by Omar Ford

Through the Looking Glass: Part 1 of 3: Google Glass to impact healthcare landscape in five important ways

Nov. 25, 2014
By Omar Ford
Nearly two and a half years ago, Google (Menlo Park, California) revealed its intention to become a dominant player in the wearable technologies market with the introduction of Project Glass – an effort that would start the path to the creation of Google Glass. Leading off with the mission statement – "We think technology should work for you – to be there when you need it and get out of your way when you don't," the company focused on changing the paradigm of how the public could conceivably access data.
Read More

Cesca files for IDE application for no-option critical limb ischemia

Nov. 24, 2014
By Omar Ford

MDD's Diagnostics Extra

Nov. 21, 2014
By Omar Ford

CombiMatrix enters into IVF market with launch of CombiPGS test

Nov. 19, 2014
By Omar Ford

Personal Genome Diagnostics launches targeted gene panel

Nov. 17, 2014
By Omar Ford

Exactech's Octane Elevate offers safer, more refined implant placement

Nov. 14, 2014
By Omar Ford

Medicrea receives FDA clearance for patient-specific spinal rod

Nov. 13, 2014
By Omar Ford

Orthofix launches clinical study to evaluate use of PEMF technology

Nov. 12, 2014
By Omar Ford
Orthofix (Lewisville, Texas) is reporting the launch of a large-scale clinical study to evaluate the use of pulsed electromagnetic fields (PEMF) technology to see if the therapy can improve osteogenesis (bone growth) in Type II odontoid fractures. More specifically, the study will examine the safety and effectiveness of PEMF treatment with the Orthofix Cervical-Stim device as an adjunct to standard immobilization with a rigid collar.
Read More

NewCo on the Go: Sentrian seeks to make sense of biometric sensors in patient monitoring

Nov. 11, 2014
By Omar Ford
A newly launched company is trying its hand at eliminating unnecessary hospitalizations and better insight on patient deterioration. Sentrian (Aliso Viejo, California) is developing the Remote Intelligence Patient Platform – a software application that could quite possibly help garner greater insight on the health of the patient.
Read More

Data from Shockwave Medical's DISRUPT PAD bodes well for firm

Nov. 10, 2014
By Omar Ford
Shockwave Medical (Fremont, California), a company that specializes in the treatment of peripheral and coronary vascular disease, reported positive clinical results from DISRUPT PAD, a single-arm multi-center study evaluating the safety and utility of Lithoplasty balloon catheters for the treatment of peripheral artery disease, at the Vascular Interventional Advances (VIVA) Annual Conference in Las Vegas.
Read More
Previous 1 2 … 71 72 73 74 75 76 77 78 79 … 227 228 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 15, 2026.
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 14, 2026
  • Cancer cell in the cross-hairs

    Selective CBL-B inhibitor with improved safety profile disclosed

    BioWorld Science
    CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
  • MSD discloses new HCN1/2 blockers

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing